NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2025
0mins
Should l Buy ?
Source: PRnewswire
DOXA Platform Expansion: NLS Pharmaceutics and Aexon Labs announced the expansion of their DOXA platform with the AEX-6xx series, focusing on small molecules that enhance arousal stability, cognition, and neuroprotection.
Lead Compound AEX-635: AEX-635, a key compound in the DOXA series, targets Multidrug Resistance-Associated Protein 1 (MRP1) to improve neuroprotective effects and drug bioavailability in conditions like Parkinson's disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
